International Journal of Drug Delivery Technology
Volume 14, Issue 2

Investigation of the Molecular Mechanisms of Sanguinaria canadensis in Treating Lung Cancer Using Network Pharmacology and Molecular Docking Techniques

Vaibhavkumar Jagtap1, Shital Bidkar2*, Manoj Shinde3, Jayprakash Suryawanshi4

1Gangamai College of Pharmacy, Nagaon, Dhule, Affiliated to Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, Maharashtra, India.

2Sharadchandra Pawar College of Pharmacy, Otur, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.

3Satara College of Pharmacy, Satara, Affiliated to Dr. Babasaheb Ambedkar Technological University, Lonere, Maharashtra, India.

4N. N. Sattha College of Pharmacy, Ahmednagar, Affiliated to Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad, Maharashtra, India.

Received: 11th January, 2024; Revised: 11th March, 2024; Accepted: 25th May, 2024; Available Online: 25th June, 2024

 ABSTRACT

This study examines the molecular mechanism that underlies the possible therapeutic benefits of Sanguinaria canadensis in the treatment of lung cancer. Through network pharmacology and molecular docking techniques, we identify 15 bioactive compounds from S. canadensis, with sanguinarine and chelerythrine being the most prominent. These compounds interact with key proteins involved in lung cancer progression, including IL-6, IL-1β, ICAM1, TNF, and MMP-9. Pathway enrichment analysis reveals significant involvement of pathways such as homologous recombination, p53 signaling, and cell cycle. GO and KEGG analyses elucidate the molecular mechanisms underlying cancer pathogenesis and highlight potential therapeutic targets. STING enrichment analysis uncovers crucial biological processes associated with STING-regulated genes, suggesting their involvement in cancer-related functions. Molecular docking studies demonstrate strong binding affinities between bioactive compounds and target proteins, indicating potential efficacy in impeding cancer-related processes. This comprehensive investigation provides insights into the therapeutic potential of S. canadensis in lung cancer treatment, warranting further experimental validation and exploration of novel therapeutic strategies.

Keywords: Sanguinaria canadensis, Lung cancer, Network pharmacology, Molecular docking, Bioactive compounds, Molecular mechanism, Pathway analysis, STING, Therapeutic targets.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.59

How to cite this article: Jagtap V, Bidkar S, Shinde M, Suryawanshi J. Investigation of the Molecular Mechanisms of Sanguinaria canadensis in Treating Lung Cancer Using Network Pharmacology and Molecular Docking Techniques. International Journal of Drug Delivery Technology. 2024;14(2):990-999.

REFERENCES

  1. Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and International Journal of Clinical Oncology. 2022 Apr;27(4):665-75. https://doi.org/10.1007/s10147-021-02108-2
  2. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn Jr Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA: a cancer journal for clinicians. 2023 Nov;73(6):620-52.https://doi. org/10.3322/caac.21785
  3. Meijer JJ, Leonetti A, Airò G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M. Small cell lung cancer: novel treatments beyond immunotherapy. InSeminars in cancer biology 2022 Nov 1 (Vol. 86, pp. 376-385). Academic Press.https://doi.org/10.1016/j. semcancer.2022.05.004
  4. Bhardwaj N, Goel B, Tripathi N, Sahu B, Jain A comprehensive review on chemistry and pharmacology of marine bioactives as antimetastatic agents. European Journal of Medicinal Chemistry Reports. 2022 Apr 1;4:100023.https://doi. org/10.1016/j.ejmcr.2021.100023
  5. Gilani SA, Imran M, Gondal TA, Ahmad I, Akram Anticancer perspectives of sanguinarine: A review. Current Bioactive Compounds. 2022 Nov 1;18(9):22-9.https://doi.org/10.2174/157 3407218666220119095852
  6. Tuzimski T, Petruczynik A, Plech T, Kaproń B, Makuch- Kocka A, Szultka-Młyńska M, Misiurek J, Buszewski B, Waksmundzka-Hajnos Determination of selected isoquinoline alkaloids from Chelidoniummajus, Mahoniaaquifolium and Sanguinaria canadensis extracts by liquid chromatography and their in-vitro and in-vivo cytotoxic activity against human cancer cells. International Journal of Molecular Sciences. 2023 Mar 28;24(7):6360.https://doi.org/10.3390/ijms24076360
  7. Danielewski M, Zielińska S, Matuszewska A, Słupski W, Włodarczyk M, Jęśkowiak I, Wiatrak B, Kowalski K, Jezierska-Domaradzka A, Ziółkowski P, Szeląg Sanguinarine‐Chelerythrine Fraction of Coptischinensis Exerts Anti‐inflammatory Activity in Carrageenan Paw Oedema Test in Rats and Reveals Reduced Gastrotoxicity. Oxidative medicine and cellular longevity. 2022;2022(1):1504929.https:// doi.org/10.1155/2022/1504929
  8. Bhandare SD, Malode SS. Cytotoxic activity of isoquinoline alkaloids and herbal extracts from selected plants against human cancer cell lines: harnessing the research potential in cancer drug discovery with modern scientific trends and technology. Toxicology Research. 2023 Dec;12(6):1034-40.https://doi. org/10.1093/toxres/tfad107
  9. Huang LJ, Lan JX, Wang JH, Huang H, Lu K, Zhou ZN, Xin SY, Zhang ZY, Wang JY, Dai P, Chen XM. Bioactivity and mechanism of action of sanguinarine and its derivatives in the past 10 years. Biomedicine & Pharmacotherapy. 2024 Apr 1;173:116406.https://doi.org/10.1016/j.biopha.2024.116406
  10. Tangelloju A, Chakravarti R, Singh R, Bhattacharya B, Ghosh A, Bhutia SK, Ravichandiran V, Ghosh A Review on the Current Status of Homeopathy in the Clinical Management of Cancer. Current Drug Targets. 2022 Oct 1;23(13):1252-60.https://doi.org/10.2174/1389450123666220816151547
  11. Wei F, Song Y, Gong A, Pan C, Zhuang Y, Zhang X, Zeng Investigating the molecular mechanism of XijiaoDihuang decoction for the treatment of SLE based on network pharmacology and molecular docking analysis. BioMed Research International. 2022;2022. 10.1155/2022/5882346
  12. Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO, Ugwuja EI, Aja PM. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases Scientific Reports. 2023 Aug 17;13(1):13398. https:// doi.org/10.1038/s41598-023-40160-2
  13. Dinengsih S, Nurdiana SW, Raharjo B, Endharti AT. In silico approaches of gandarusa (JusticiagendarussaBurm. f.) potential for osteoporosis prevention via EGF pathway. Journal of Pharmacy &Pharmacognosy 2024;12(3):439-52.https:// doi.org/10.56499/jppres23.1781_13.3.439
  14. Yan L, Zhang Z, Liu Y, Ren S, Zhu Z, Wei L, Feng J, Duan T, Sun X, Xie T, Sui X. Anticancer activity of erianin: Cancer-specific target prediction based on network Frontiers in Molecular Biosciences. 2022 Mar 17;9:862932.https://doi. org/10.3389/fmolb.2022.862932
  15. Liu Q, Lee B, Xie Small molecule modulation of microbiota: a systems pharmacology perspective. BMC bioinformatics. 2022 Sep 29;23(Suppl 3):403. https://doi.org/10.1186/s12859-022-04941-2
  16. Alameer A, Chicco geoCancerPrognosticDatasetsRetriever: a bioinformatics tool to easily identify cancer prognostic datasets on Gene Expression Omnibus (GEO). Bioinformatics. 2022 Mar 15;38(6):1761-3. https://doi.org/10.1093/bioinformatics/btab852
  17. Zhang L, Cai J, Xiao J, Ye Identification of core genes and pathways between geriatric multimorbidity and renal insufficiency: potential therapeutic agents discovered using bioinformatics analysis. BMC Medical Genomics. 2022 Oct 8;15(1):212. https://doi.org/10.1186/s12920-022-01370-1
  18. deVries I, Perrakis A, Joosten PDB‐REDO in Computational‐ Aided Drug Design (CADD). Open Access Databases and Datasets for Drug Discovery. 2024 Feb 5:201-29. https://doi. org/10.1002/9783527830497.ch7
  19. Liu Y, Cao Protein– Ligand Blind Docking Using CB-Dock2. InComputational Drug Discovery and Design 2023 Sep 8 (pp. 113-125). New York, NY: Springer US. https://doi.org/10.1007/978-1-0716-3441-7_6
  20. Wakale V, Kachave R, Gholap P, Mahajan K, Tare H. Design and Discovery of Genistein-based Drugs as a Potential Tyrosine Kinase Inhibitor for Lung Adenocarcinoma through Hybrid In-silico Methods. International Journal of Drug Delivery Technology. 2023;13(4):1422-1427.
  21. Deore S, Tajane P, Bhosale A, Thube U, Wagh V, Wakale V, Tare 2-(3, 4-Dihydroxyphenyl)-5, 7-Dihydroxy-4H-Chromen- 4-One Flavones Based Virtual Screening for Potential JAK Inhibitors in Inflammatory Disorders. International Research Journal of Multidisciplinary Scope (IRJMS), 2024; 5(1): 557-567.
  22. Deore S, Wagh V, Tare H, Kayande N, Thube U. Molecular Docking Analysis of Potentilla fulgens Polyphenols against Estrogen Receptors Involved in Breast Cancer. International Journal of Pharmaceutical Quality 2024;15(1):346-350.
  23. Deore S, Wagh V, Thorat M, Bidkar S, Tare In-silico Discovery of Potential Dengue Type 2 Virus NS1 Inhibitors: A Natural Ligand Zingerone-Derived 3-Point Pharmacophore Screening and Structure-Guided Blind Docking Study. International Journal of Pharmaceutical Quality Assurance. 2024;15(1):414-420.